• Engineered LRRK2 kinase-domain inhibitor scaffold 39m ago
  • Huntingtin polyQ-tract recognizer 39m ago
  • TDP-43 N-terminal stabilizer 39m ago
  • α-Synuclein aggregation inhibitor 39m ago
  • Anti-Aβ42 binder de novo 39m ago

answer C

market 50% proposed
Composite
—
Novelty
—
Feasibility
—
Impact
—
Mechanistic
—
Druggability
—
Safety
—
Confidence
—

This hypothesis has no description yet.